SML3961

Paricalcitol

≥98% (HPLC)

• 同義詞: (1R,3R)-5-((E)-2-((1R,3aS,7aR)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1H-inden-4(2H,5H,6H,7H,7aH)-ylidene)ethylidene)cyclohexane-1,3-diol, (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol, 19-Nor-1alpha,25-dihydroxyvitamin D2
• 經驗公式（希爾表示法）: C₂₇H₄₄O₃
• CAS號碼: 131918-61-1
• 分子量：: 416.64
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: -10 to -25°C

描述

生化／生理作用

Agonist for the calcitriol (Vitamin D receptor); Vitamin D analog; Antihyperparathyroid.

Paricalcitol is Vitamin D analog that acts as an agonist for the calcitriol receptor (Vitamin D receptor, VDR). It suppresses parathyroid hormone (PTH) gene transcription and PTH secretion and has been used clinically because of its antihyperparathyroid activity without inducing hypercalcemia or hyperphosphatemia. There is growing evidence that vitamin D either directly or indirectly affects cardiac structure and function. Paricalcitol showed improvement of cardiac function after myocardial infarction in mice with decreases in biomarkers, apoptosis, inflammation, and fibrosis.

安全資訊

• 象形圖: GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H301 + H311,H330,H372
• 防範說明: P260 - P264 - P280 - P302 + P352 + P312 - P304 + P340 + P310 - P314
• 危險分類: Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral
• 儲存類別代碼: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable